14 Oct Webinar Hero


State-of-the-Art Immunotherapy in ALL

Wednesday, 14 Oct 2020
20:00-21:00 (UTC+8)



Immuno-oncology approaches have entered clinical practice, with tremendous progress particularly in the field of T cell-engaging therapies for ALL over the past decade. The webinar with renowned haematologists Prof Elias Jabbour (MD Anderson Cancer Centre, USA) and Dr Jae H Park (MSKCC, USA) provides an overview of the current innovative T cell-engaging approaches for ALL treatment.

This webinar reviews current clinical data of Bispecific T cell Engager (BiTE) therapy as well as its challenges relating to treatment administration and patient monitoring, toxicities and resistance to treatment, and novel strategies to overcome these hurdles. Meanwhile, the landmark trials for Chimeric Antigen Receptor (CAR) T cell Therapy in ALL, associated toxicities, as well as efforts to improve durable response to therapy will also be highlighted in this webinar.






BiTEs treatment in B-ALL landscape

Prof Elias Jabbour

Professor, Department of Leukaemia
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, Texas

Dr. Jabbour joined the MD Anderson Cancer Center faculty in 2007 and is currently a Professor of Medicine in the Department of Leukemia. He is actively involved in developmental therapeutics research in leukaemia. Over the past 5 years he has assisted in developing chemotherapeutic and biologic agents in leukaemias and contributed to the development of others.

He was also actively associated with frontline studies of nilotinib and dasatinib which resulted in FDA approval of these agents for frontline CML therapy in 2010.

He is leading efforts to test triple therapy in AML (nucleoside analogs + anthracyclines + cytarabine), which may may change the standard of care for the management of patients with AML. Furthermore, he is also currently investigating the benefit of adding humanized monoclonal antibody for the treatment of patients with ALL (ofatumumab and HCVAD) and collaborating in the development of monoclonal antibody studies in adult ALL.

CAR T Therapy in B-ALL and Treatment Advancement

Dr Jae H Park

Associate Attending Physician
Director, Adult ALL Program
Clinical Director, Cellular Therapeutics Service
Memorial Sloan Kettering Cancer Center

Dr Park is a haematologist-oncologist specialising in the care of patients with leukemia.

As an active translational investigator, he has spent time both in the laboratory and in clinics to bring new and innovative treatments to patients with leukemia.  He has published extensively and his research has been supported by ASH, ASCO, and LLS.  He is particularly interested in developing more-effective and personalised therapies for patients with acute and chronic lymphoid leukemia, and is the lead investigator of several clinical trials of CAR T cells, BiTEs, ADCs and other targeted therapies in patients with ALL, CLL and HCL.   



Dr Lim Ziyi

Medical Director, Centre for Clinical Haematology
Senior Consultant in Haematology
Mount Elizabeth Novena Hospital

President, Bone Marrow Donor Programme (BMDP)

Dr Lim Zi Yi is the Medical Director of CFCH and a Senior Consultant in Haematology at the Mount Elizabeth Novena Hospital (Singapore). He has a specialist interest in Haemato-oncology and Haematopoietic Stem Cell Transplantation.

He received his medical degree from the University of Edinburgh, UK and subsequently underwent specialist training in haemato-oncology at Kings College Hospital, London where he helped to develop it into one of the largest allogeneic haematopoietic stem cell transplant centres in Europe. 


This educational material is intended to provide information on research activities and may refer to products not approved for use in Singapore and/or unapproved uses of products approved in Singapore. The views expressed in this presentation are those of the presenter. Amgen Singapore does not endorse the promotion of unapproved products or indications.

This webinar is sponsored with an educational grant from Amgen. Participants are invited to connect with AMGEN via: bit.ly/Webinar_AMGEN_Consent